Sign in

Pfizer, BioNTech seek US emergency nod for Covid-19 vaccine in adolescents

In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.

Published on: Apr 9, 2021, 23:22:55 IST
ReutersPosted by
Share
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

Pfizer Inc and its German partner BioNTech SE said on Friday they have requested the US Food and Drug Administration to expand the emergency use of their Covid-19 vaccine in adolescents aged 12 to 15.

The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16. (AFP)
The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16. (AFP)

In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.

Whether Covid-19 vaccines work and are safe to use on children is one of the big questions drugmakers are trying to answer. Inoculating children and young people is considered a critical step toward reaching "herd immunity" and taming the pandemic, according to experts.

The companies plan to request similar rulings by other regulatory authorities globally in the coming days.

The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16.

  • Harshit Sabarwal
    ABOUT THE AUTHOR
    Harshit Sabarwal

    Online journalist based in New Delhi. I read about global conflicts and the drug war in Mexico.